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Introduction {#sec001}
============

Eosinophils are the main effector cells responsible for the severity of asthma. Infiltrated eosinophils in the bronchial mucosa cause damage to the airway epithelium and related nerves through the release of granule major basic proteins, lipid mediators, and reactive oxygen species \[[@pone.0151758.ref001]\]. Besides, eosinophils are a source of several molecules, such as TGF-α, TGF-ß, and FGF-2 \[[@pone.0151758.ref002]--[@pone.0151758.ref004]\], implicated in tissue remodeling processes. The consequences of excessive repair processes by eosinophils include deposition of extracellular matrix (ECM) proteins, smooth muscle increases, goblet-cell hyperplasia, and angiogenesis, which lead to airway hyper-responsiveness and airway obstruction \[[@pone.0151758.ref005]\]. Therefore, it is critical in the treatment of asthma to control eosinophil infiltration into the airway.

Asthma is a chronic inflammatory airway disease characterized by the infiltration of T cells, mast cells, and eosinophils into the respiratory region \[[@pone.0151758.ref006]\]. The clinical phenotype that defines allergic asthma is a coordinated product that results from the interactions between susceptible genes, external noxious materials, environment, defective barrier system, and immunological responses \[[@pone.0151758.ref007]\]. It is well known that CD4^+^ T-helper type lymphocytes play a prominent role in asthma, establishing T~H~2-skewed immune environments with coordinate production of T~H~2 cytokines, such as IL-4, IL-5 and IL-13, which drive inflammation associated with allergic responses through the recruitment and activation of T cells, eosinophils, and mast cells \[[@pone.0151758.ref008]\]. IL-4 is a pleiotrophic cytokine representing T~H~2 immunity. One of the important roles of IL-4 is to induce eosinophil attracting chemokines; chemokine (C-C motif) ligand 11, 24 and 26 (CCL11, 24 and 26; also known as Eotaxin-1, -2 and -3) \[[@pone.0151758.ref009]--[@pone.0151758.ref011]\].

The inflammation occurring in asthma is often described as eosinophilic \[[@pone.0151758.ref012]--[@pone.0151758.ref014]\]. During asthma progression, eosinophils are infiltrated into the airway in response to eosinophil chemotactic factors such as CCL11, 24 and 26, which are secreted by airway epithelial cells \[[@pone.0151758.ref015], [@pone.0151758.ref016]\]. CCL26 is the most potent eosinophil attracting factor and its increased level in the serum is correlated with the severity of asthma. While the expression of CCL11 and CCL24 is observed in the lung tissues of non-challenged asthmatic patients, CCL26 is only expressed in response to allergen challenge, indicating that CCL26 plays a distinct biological role from that of CCL11 and CCL24 \[[@pone.0151758.ref017]\]. In addition, the increased level of CCL26 is also associated with other kinds of eosinophilic diseases, such as atopic dermatitis, chronic rhinosinusitis, eosinophilic esophagitis and Churng-Strauss vasculitis \[[@pone.0151758.ref018]\]. Many pharmaceutical drugs for the treatment of asthma, for example glucocorticoids, are mainly targeting immunosuppression and anti-inflammatory effects. Dexamethasone (DEX), a synthetic glucocorticoid, diminished the induction of *CCL26* mRNA expression in human lung epithelial cells and dermal fibroblasts \[[@pone.0151758.ref017]\]. However, prolonged administration of this type of steroid medication triggers many side effects such as osteoporosis, hyperlipidemia, cardiovascular diseases, behavioral and cognitive changes, and gastritis and peptic ulceration \[[@pone.0151758.ref019]\]. The development of a therapeutic agent for the treatment of asthma without accompanying side effects is required.

1-Palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol (PLAG) is a lipid molecule naturally occurring in a variety of seed oils, bovine udder, and deer horns. In traditional oriental medicine, extracts from the antlers of Sika deer (*Cervus nippon* Temminck) have been extensively used for alleviating various symptoms such as anorexia and fatigue, invigorating vital energy, and nourishing the blood \[[@pone.0151758.ref020]\]. In a murine model of ovalbumin (OVA)-induced asthma, PLAG reportedly alleviated the allergic asthma symptoms including the recruitment of inflammatory cells, methacholine responsiveness, mucus overproduction, and T~H~2 cytokine production \[[@pone.0151758.ref021]\]. It was also recently reported that PLAG modulates T~H~2 immunity by reducing the phosphorylation of signal transducer and activator of transcription 6 (STAT6), which inhibits the expression of affected genes such as IL-4 \[[@pone.0151758.ref022]\]. Although CCL26 is mainly produced in response to IL-4 via STAT6 pathway \[[@pone.0151758.ref023]\], little is known about the direct efficacy of PLAG on the regulation of CCL26. In this study, we discovered that PLAG can inhibit IL-4 induced CCL26 expression from epithelial cells by interfering with STAT6 signaling pathway, resulting in the control of eosinophil chemotaxis in an allergic asthma model. These findings suggest that PLAG can be developed as a therapeutic agent that ameliorates symptoms of asthma by suppressing CCL26 production from epithelial cells and the following eosinophil chemotaxis.

Materials and Methods {#sec002}
=====================

Reagents and cell culture {#sec003}
-------------------------

Human CCL26/CCL26 DuoSet ELISA kit was purchased from R&D systems (USA). Recombinant human IL-4, murine stem cell factor (SCF), murine FMS-like tyrosine kinase-3 (FLT3) ligand, and murine IL-5 were purchased from PeproTech (USA). Tri Reagent® was purchased from MRC Inc (USA). Attractene Transfection Reagent was purchased from QIAGEN Inc (USA). AS1517499 was purchased from Axon Medchem (USA). PLAG was obtained from Enzychem Lifesciences (Daejeon, South Korea), and diluted in dimethyl sulfoxide (DMSO, Sigma-Aldrich, USA) for the treatments. The same amount of DMSO were treated as negative control in every in vitro experiment. Anti-STAT6 and anti-phospho-STAT6 antibodies were purchased from Cell Signaling Technology (USA). Chicken OVA, aluminum potassium sulfate, and DEX were purchased from Sigma-Aldrich. PLAG was obtained from Enzychem Lifesciences Corporation (South Korea). A human keratinocyte cell line, HaCaT, and a human alveolar basal epithelial cell line, A549, were obtained from ATCC (USA) and cultured in DMEM and RPMI 1640 (Welgene, South Korea) respectively containing 10% FBS (Welgene), 100 U/mL penicillin, and 100 μg/mL streptomycin (Sigma-Aldrich) at 37°C in a humidified atmosphere with 5% CO~2~.

RNA isolation and Reverse transcription polymerase chain reaction (RT-PCR) {#sec004}
--------------------------------------------------------------------------

Total RNAs from A549 and HaCaT were isolated using TRI Reagent® (MRC Inc., USA) according to the manufacturer's instructions. 500 ng of total RNA was reverse-transcribed using primer (oligo-dT) and M-MLV RT enzyme (Promega, USA) for cDNA synthesis, followed by conventional PCR. The following primers were used in this study: 5'-AGTTGAAGGATGCGGGAGTA-3' and 5'-TCTCCAGTTGAACATATCAAGCA-3' for VCAM-1; 5'- GCCAGCGACTCCCCCACAAC-3' and 5'- AAGCTGCGCCCGTTGTCCTC-3' for ICAM-1; 5'- GTTCCTCTCCGAGCTCACC-3' and 5'-GAGTTGTTCCAGCCCACATT-3' and 5'- GAGTTGTTCCAGCCCACATT-3' for MIF; 5'-GGCAGCCCTCGCTGTCATCC-3' and 5'-GCCCTTCAAGGAGCGGGTGG-3' for CCL5; 5'- AGCACCTGGACAAGAAAACCC-3' and 5'- CCCCCATGAGGTAGAGAAGG-3' for CCL7; 5'-AATGTCCCCAGAAAGCTGTG-3' and 5'- TCATCTTTGCCAGGACCTTT-3' for CCL11; 5'- GGAAAGCTCACACCCTGAAGA-3' and 5'-CCAAACCAGCAACAAGTCAAATA-3' for CCL13; 5'- AGGGACCTGCACACAGAGAC-3' and 5'-AGGTAGTCCCGGGAGACAGT-3' for CCL17; 5'- GCCTTCTGTTCCTTGGTGTC-3' and 5'- TGTACCTCTGGACCCACTCC-3' for CCL24; 5'- AATTGAGGCTGAGCCAAAGA-3' and 5'- GGGTCCATGTAGCCTTCAGA-3' for CCL26; 5'- CCATCACCATCTTCCAGGAG-3' and 5'- ACAGTCTTCTGGGTGGCAGT-3' for GAPDH.

Enzyme-linked immunosorbent assay (ELISA) {#sec005}
-----------------------------------------

For CCL26 immunoassay, A549 cells (0.5x10^6^ cells/mL) were seeded in 48-well plates (Corning, USA). The cells were pretreated with different doses of PLAG, AS1517499 and JAK I inhibitor followed by stimulation with IL-4 (10 ng/mL). After incubation, the supernatants were collected and analyzed by ELISA. The level of CCL26 was detected by Duo kit (R&D Systems, USA) according to the manufacturer's instruction. Optical densities were measured at 450 nm using a Bio-Rad Model 550 microplate reader (Bio-Rad Laboratories, USA). The concentrations were calculated from a standard curve generated by a curve-fitting program.

The production of mouse CCL26 from mouse airway tissues was measured by ELISA using Eotaxin-3 ELISA kit (MyBiosource Inc., USA) according to the manufacturer's instruction.

Western blot analysis {#sec006}
---------------------

Cells were lysed with RIPA buffer composed of 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 2 mM EDTA, 1% NP-40, 0.5% sodium deoxycholate, and 0.1% SDS containing protease inhibitor cocktail (Roche, USA) and Halt^TM^ phosphatase inhibitor (Thermo Scientific, USA). The lysate was heated in 5x protein sample buffer at 100°C for 15 min, separated by 10% SDS-PAGE, and transferred onto PVDF membranes (Millipore Corporation, USA). The membrane was blocked by 5% (w/v) bovine serum albumin (Bioworld, USA) in PBS containing 0.05% (v/v) Tween 20 (PBST) for 1 h and incubated overnight at 4°C with the primary antibody against STAT6 and phospho-STAT6 (1:1000; rabbit monoclonal IgG). Following the addition of horseradish peroxidase (HRP)-labeled secondary antibodies (Santa Cruz Biotechnology, USA) for 1 h, the blots were visualized using Immobilion Western Chemiluminescent HRP Substrate (Millipore Corporation).

Transfection and luciferase assay {#sec007}
---------------------------------

A549 cells (2x10^5^/mL) were seeded into 48-well plates and grown overnight. Transfection was performed by using Attractene transfection reagent according to the manufacturer's instructions. Briefly, a total of 1--2 μg/well reporter luciferase plasmid containing four tandem copies of the STAT6 binding site (p4xSTAT6- Luc2P; Addgene, USA) was transfected. After 18 h, the cells were treated with different concentrations of PLAG for 1 h and then stimulated with IL-4 (10 ng/mL) for 24 h. Transient expression of the reporter gene was quantified using Dual-Glo® luciferase assay system (Promega) on the TD-20/20 Turner Luminometer (Promega).

Confocal microscopy {#sec008}
-------------------

A549 cells (2x10^5^ cells/mL) were seeded on a glass cover slip and grown overnight. The cells were treated with different concentrations of PLAG and stimulated with IL-4 (10 ng/mL) for 30 min. Cells were fixed for 20 min with 4% para-formaldehyde in PBS, permeabilized with methanol for 10 min, blocked with 1% BSA and incubated overnight with antibody against phospho-STAT6 at 4°C. Alexa Fluor 594-conjugated donkey antibody to rabbit (Life Technologies, USA) was used as a secondary antibody at 1:1000 dilution. Cover slips were washed, dried and mounted in Prolong Gold Antifade Reagent with DAPI (Roche) and visualized by Zeiss LSM 510 Meta (Zeiss, Germany) at ambient temperature. The images were processed and analyzed by Image J (NIH, USA).

Animals {#sec009}
-------

Specific pathogen-free Female BALB/c mice (6--8 weeks of age) were purchased from Koatech Corporation (South Korea). Mice were housed in a specific pathogen-free facility under consistent temperature and light cycles. All experimental procedures were approved by the Institutional Animal Care and Use Committee of the Korea Research Institute of Bioscience and Biotechnology performed in compliance with the National Institutes of Health Guidelines for the care and use of laboratory animals and Korean national laws for animal welfare.

Mouse allergic asthma {#sec010}
---------------------

Mice were divided into six groups (n = 3 for each group). To induce allergic asthma, the mice were sensitized by injecting 20 μg of chicken egg albumin (OVA, Sigma-Aldrich) mixed with 2 mg of aluminum potassium sulfate (Sigma-Aldrich) in 100 μL of PBS intraperitoneally (i.p.) on day 0 and 14. From day 15 to 21, different doses of PLAG (10, 50, 250 mg/Kg) or DEX (3 mg/Kg) were administrated to the mice by oral gavage daily after being emulsified by flushing thoroughly through three-way valves. On day 20, the mice were anaesthetized with i.p. injection of 2,2,2-Tribromoethanol (Avertin, Sigma-Aldrich) dissolved in tert-Amyl alcohol (500 mg/Kg) and then challenged with 100 μg of OVA in 50μl PBS intranasally (i.n.). Forty-eight-hour after OVA challenge, the mice were sacrificed by an i.p. injection of pentobarbital (Hanlim Pharm. C., South Korea), and tracheostomy was performed. To obtain bronchoalveolar lavage fluid (BALF), 0.75mL of ice-cold PBS was infused to the lung and withdrawn via tracheal cannulation two times. Immune cell populations in BALFs were analyzed by complete blood count (CBC) using a hematology analyzer, Mindray BC-5300 (China).

Flow cytometry {#sec011}
--------------

BALF cells or BM-derived eosinophils were resuspended with FACS buffer (1% FBS in PBS) and stained with Siglec-F-PE and CD11b PE-Cy7 (BD Biosciences, USA) for 30min at 4°C. Then the cells were washed with FACS buffer twice and analyzed by FACS CANTO flow cytometer (BD Biosciences). FACS data were processed by Flow Jo software (Tree Star, USA).

Histopathology {#sec012}
--------------

Immediately after collecting BALF samples, lung tissues were incised and fixed in ice-cold 10% formalin. Each tissue was embedded in paraffin, sectioned at 4-μm thickness, and deparaffinized after being mounted on a slide glass. The slides were stained with hematoxylin and eosin (H&E) solution, and examined under light microscopy (Olympus, Japan).

Murine eosinophils and migration assay {#sec013}
--------------------------------------

Murine eosinophils were differentiated from bone marrow (BM) cells isolated from BALB/c mice. Briefly, BM cells were collected from the femurs of BALB/c mice and cultured in RPMI 1640 containing 20% FBS and 100 U/mL penicillin/streptomycin. 80 ng/mL of SCF and FLT3 ligand were treated to the medium during initial culture. On day 4, cells were transferred to a medium containing 10 ng/mL of IL-5 and subcultured every other day up to day 14, maintaining cell density at 1x10^6^ cells/mL.

A549 cells were pretreated with different concentrations of PLAG for 1h and stimulated with IL-4 for 72 h. The supernatants were used for migration assay. The differentiated eosinophils (2x10^5^ cells/100μL) and EoL-1 cells (1x10^6^ cells/100μL) were added to the upper chamber of Transwell 24-well plates with 5 μm polycarbonate membrane filters (Falcon, USA). Six hundred microliters of CCL26-containing supernatant was added to the bottom chamber and incubated for overnight. The total numbers of migrated eosinophils were counted by trypan blue staining.

Cell proliferation assay {#sec014}
------------------------

Cell viability was checked by colorimetric water-soluble tetrazolium salt (WST) assay using EZ-CYTOX (DaeilLab Service, South Korea) according to the manufacturer's instructions. Briefly, A549 cells (5x10^4^ cells/well) were seeded in 96-well plates, pretreated with different doses of PLAG, and then stimulated with IL-4 (10 ng/mL) for 72 h. The number of viable cells was measured at 450 nm of the absorbance using a Bio-Rad Model 550 microplate reader.

Statistical Analysis {#sec015}
--------------------

The significance of differences between experimental groups was analyzed using Student's unpaired t-test. Mean values from three different samples were depicted in the graph. Differences in means were considered significant if *p*\<0.05. Each bar represents the mean ± SD.

Analysis of *CCL26* expression in mouse tissues {#sec016}
-----------------------------------------------

Lung inflammation was induced by intranasal injection of LPS (25 mg/Kg) into Balb/c mice (7 week, male) for 15 h. PBS was injected intranasally as negative control. Mice were sacrificed by cervical dislocation and lung tissues were isolated. Total RNAs were purified from the lung tissues followed by RT-PCR analysis as described in 'Materials and Method'. Primer sequences were mCCL26-F; 5'-CTTCGATTTGGGTCTCCTTG-3', and mCCL26-R; 5'-TCACTGGTGCAGCTCTTGTC-3'. The PCR product was purified and analyzed by sequencing (Macrogen, South Korea).

Results {#sec017}
=======

*PLAG* inhibits *IL-4* induced *CCL26* expression {#sec018}
-------------------------------------------------

To find the relationship of PLAG function in asthmatic pathogenesis, we analyzed the expression of various genes known to be involved in the regulation of eosinophil migration by conventional RT-PCR. The expression of CCL26 was distinguished from other genes in that it was significantly inhibited by PLAG in a dose-dependent manner ([Fig 1A](#pone.0151758.g001){ref-type="fig"}). Two of the other Eotaxin family member, CCL11 and CCL24, and adhesion molecules, VCAM-1 and ICAM-1, were not expressed in response to IL-4 stimulation nor affected by PLAG. Macrophage migration inhibitory factor (MIF), CCL5 (RANTES) and CCL13 (MCP-4), which are known to induce eosinophil infiltration into lesional sites \[[@pone.0151758.ref024]--[@pone.0151758.ref026]\], also showed no significant changes by IL-4 and PLAG. The expression of CCL17 was induced by IL-4, but was not affected by PLAG. Interestingly, the expression of CCL7 was synergistically diminished by IL-4 and PLAG. The effect of PLAG on IL-4 induced CCL26 secretion in A549 cells was also verified by ELISA. PLAG caused a concentration- and time-dependent inhibition of IL-4 induced CCL26 production from the epithelial cells ([Fig 1B and 1C](#pone.0151758.g001){ref-type="fig"}). PLAG effect on CCL26 expression was confirmed in the other epithelial cell line, HaCaT ([Fig 1D and 1E](#pone.0151758.g001){ref-type="fig"}). These findings suggest that PLAG is able to inhibit IL-4 induced production of CCL26 from epithelial cells.

![IL-4 induced CCL26 expression is inhibited by PLAG.\
(A) A549 cells were treated with various doses of PLAG (1, 5, 10, 50 μg/mL) for 1 h and stimulated with IL-4 (10 ng/mL) for 24 h. The mRNA levels of following genes, VCAM-1, ICAM-1, MIF, CCL5, CCL7, CCL11, CCL13, CCL17, CCL24, and CCL26 were analyzed by conventional RT-PCR. Each reaction was repeated three times and representative images were displayed. GAPDH was used as an internal control. (B) The culture supernatant was harvested at 48 h, and the protein level of CCL26 was evaluated by ELISA. PLAG decreased CCL26 secretion from A549 cells in a dose-dependent manner. \**p*\<0.001, \*\*\**p*\<0.05. (C) A549 cells were pretreated with PLAG (10 μg/mL) for 1 h and stimulated with IL-4 (10 ng/mL) for various lengths of time. PLAG decreased CCL26 secretion from A549 cells from the early time point. NC; negative control. \**p*\<0.001, \*\**p*\<0.01, \*\*\* *p*\<0.05. (D) HaCaT cells were treated with various doses of PLAG and stimulated with IL-4 (20 ng/mL) for 24 h. The mRNA levels of CCL 26 were analyzed by RT-PCR. (E) PLAG also decreased CCL26 secretion from HaCaT cells in a dose-dependent manner. \**p*\<0.001, \*\*\**p*\<0.05.](pone.0151758.g001){#pone.0151758.g001}

*PLAG* inhibits transcriptional activity of *STAT6* {#sec019}
---------------------------------------------------

It is well known that IL-4 induced CCL26 expression is mediated by JAK1/STAT6 signaling pathway. We confirmed the signaling pathway of CCL26 expression in the epithelial cells by treating with a STAT6 inhibitor, AS1517499. IL-4 induced production of CCL26 was decreased by AS1517499 ([Fig 2A](#pone.0151758.g002){ref-type="fig"}). An unspecified JAK inhibitor, JAK inhibitor I, also exhibited suppressive effect on IL-4 induced CCL26 expression (data not shown). Promoter analysis using a reporter construct containing STAT6-binding domains confirmed the modulatory effect of PLAG on the transcriptional activity of STAT6 in the epithelial cells ([Fig 2B](#pone.0151758.g002){ref-type="fig"}). Transcriptional activity of STAT6 was remarkably inhibited by PLAG in a dose-dependent manner. Additional reporter analysis using HEK Blue IL-4/IL-13 cell supported PLAG effect on the regulation of STAT6 activities ([Fig 2C](#pone.0151758.g002){ref-type="fig"}). The phosphorylation of STAT6 was effectively inhibited by PLAG dose-dependently ([Fig 2D and 2E](#pone.0151758.g002){ref-type="fig"}). In addition, PLAG decreased the nuclear translocation of phosphorylated STAT6 ([Fig 2F](#pone.0151758.g002){ref-type="fig"}). These data indicate that PLAG is able to block STAT6 phosphorylation and transcriptional activities resulting in the decrease of CCL26 expression.

![PLAG inhibits IL-4 induced STAT6 phosphorylation.\
(A) Various concentration of a STAT6 inhibitor (STAT6i, AS1517499) were treated onto A549 cells which were activated by IL-4 (10 ng/mL), and showed inhibitory effect on the secretion of CCL26 from the epithelial cells in a concentration-dependent manner. \**p*\<0.001, \*\**p*\<0.01. (B) Reporter construct containing luciferase gene regulated by STAT6 activity was transfected into A549 cells and the effect of PLAG on the expression of the luciferase gene was analyzed by Dual-Glo luciferase system. The inhibitory effect of PLAG on STAT6 activity resulted in the decrease of luciferase expression. \**p*\<0.001, \*\**p*\<0.01. (C) The effect of PLAG on the inhibition of IL-4-induced SEAP activity was evaluated in HEK Blue IL-4/IL-13 cells. \**p*\<0.001, \*\**p*\<0.01. (D-E) Cellular extracts of IL-4 and/or PLAG treated epithelial cells were analyzed by Western blotting. PLAG decreased the phosphorylation of STAT6 with dose dependency in both A549 (D) and HaCaT (E). (F) Confocal microscopy showed that IL-4 induced nuclear localization of phosphorylated STAT6, which was inhibited by the co-treatment of PLAG.](pone.0151758.g002){#pone.0151758.g002}

Administration of *PLAG* attenuates asthma phenotypes in an allergic asthma model {#sec020}
---------------------------------------------------------------------------------

To test the effect of PLAG-mediated CCL26 inhibition on the regulation of eosinophil infiltration into airway inflammatory sites, PLAG was administered per orally into OVA-sensitized and -challenged mice ([Fig 3A](#pone.0151758.g003){ref-type="fig"}). DEX was treated as a comparative drug. A large number of blood cells including eosinophils were infiltrated into the lung tissues of OVA-challenged mice compared with the control group, which was administered with PBS ([Fig 3B and 3C](#pone.0151758.g003){ref-type="fig"}). Most of infiltrated cells were concentrated at the peribronchiolar and perivascular lesions. The infiltration of immune cells was decreased by PLAG administration similarly with DEX treatment. CCL26 concentration in bronchoalveolar lavage fluid (BALF) was increased in OVA-challenged mice, which was decreased by DEX or PLAG administration ([Fig 3D](#pone.0151758.g003){ref-type="fig"}).

![PLAG alleviates inflammatory phenotypes in allergic asthma model.\
(A) Mice were sensitized and challenged by OVA, and the efficacy of PLAG and DEX was tested in the generated asthma model as depicted. (B-C) The lung tissues from the OVA-sensitized and--challenged mice were stained with H&E, and the representative images were displayed (X200 magnification, B). Infiltrated immune cells were counted, calculated and displayed as inflammation index. Eosinophils from each of the three mice per treatment group were analyzed morphometrically and mean eosinophil counts per 50 × 50 μm area ± SD were displayed. Four such areas were measured from each tissue section. PLAG was the most effective with a dose of 50 mg/Kg as showed in (B) and calculated in (C). \**p*\<0.001. (D) The expression level of CCL26 in BALFs of OVA-challenged mice was analyzed by ELISA. Each sample was analyzed in triplicate and displayed as mean ± SD. \**p*\<0.001.](pone.0151758.g003){#pone.0151758.g003}

CBC analysis of the BALFs showed that most blood cell populations were massively increased in OVA-challenged mice, which were decreased by PLAG or DEX treatment ([Fig 4A](#pone.0151758.g004){ref-type="fig"}). Especially, the number of infiltrated eosinophils into the airway of OVA-challenged mice was decreased in PLAG-treated mice ([Fig 4A](#pone.0151758.g004){ref-type="fig"}). FACS analysis also confirmed the inhibitory effect of PLAG on the infiltration of eosinophils into inflammatory airways. PLAG or DEX administration decreased the number of polymorphonuclear (PMN) cells ([Fig 4B](#pone.0151758.g004){ref-type="fig"}) or SiglecF+/CD11b+ eosinophils ([Fig 4C](#pone.0151758.g004){ref-type="fig"}) in the BALFs from OVA-challenged mice.

![PLAG decreases eosinophil infiltration into the airways of asthmatic mice.\
(A) Cells were harvested from the BALFs of OVA-challenged mice and analyzed by CBC. The number of infiltrated immune cells were increased in OVA-challenged mice. PLAG or DEX treatment inhibited immune cell infiltration into airways to the level of normal control. (B) After CBC, cells were collected from the BALF, and analyzed by flow cytometry. PLAG and DEX treatment induced the recovery of PMN cell populations which were increased in the allergic mice. (C) SiglecF+/CD11b+ eosinophils were increased in the OVA-challenged mice, which were decreased in PLAG- or DEX-treated mice.](pone.0151758.g004){#pone.0151758.g004}

*PLAG* inhibits eosinophil migration by suppressing *CCL26* expression {#sec021}
----------------------------------------------------------------------

To explore whether PLAG is directly able to inhibit eosinophil migration, we performed a chemotaxis assay using murine eosinophils differentiated from bone marrow cells and a human eosinophil cell line, EoL-1. Differentiation of eosinophils from mouse bone marrow cells was verified by analyzing surface presentation of eosinophil specific markers in the differentiated cells. SiglecF+/CD11b+ cells were increased in the differentiated murine eosinophils ([Fig 5A](#pone.0151758.g005){ref-type="fig"}). In addition, the expression of C-C chemokine receptor 3 (CCR3), a cell surface receptor for CCL26, was also increased in differentiated murine eosinophils ([Fig 5B](#pone.0151758.g005){ref-type="fig"}). CCL26-containing medium from IL-4 stimulated A549 cells caused chemotactic invasion of differentiated murine eosinophils ([Fig 5C](#pone.0151758.g005){ref-type="fig"}), which was inhibited by pre-treatment of PLAG in a concentration-dependent manner. The invasion of EoL-1, a human eosinophil, was also inhibited by PLAG in a similar pattern ([Fig 5D](#pone.0151758.g005){ref-type="fig"}). Any cytotoxic effects were not detected in A549 cells by PLAG treatment ([Fig 5E](#pone.0151758.g005){ref-type="fig"}). These findings suggest that the decrease of CCL26 production from epithelial cells by PLAG led to the suppression of eosinophil migration.

![PLAG inhibits eosinophil migration in vitro.\
(A) Murine eosinophils were differentiated from BM cells by treating SCF, FLT3 ligand and IL-5 for 2w. The differentiated cells were analyzed by FACS staining with SiglecF and CD11b. SiglecF+/CD11b+ cells were increased in the differentiated cells to \~25%. (B) CCR3 expression was increased in the differentiated murine eosinophils. (C-D) The supernatant of IL-4 and/or PLAG-treated A549 cells was prepared and used for the migration assay as described in Materials and Methods. The transmigration of eosinophil was decreased by PLAG treatment in both murine BM-derived eosinophils (C) and human eosinophil cell line, EoL-1 (D). \**p*\<0.001, \*\**p*\<0.01. (E) PLAG did not exhibit any cytotoxic effects on A549 cells at various concentrations.](pone.0151758.g005){#pone.0151758.g005}

Discussion {#sec022}
==========

In the Orient, many natural products have been used as medical herbs for the treatment of asthma, but the modes of action of such medicines are often unclear \[[@pone.0151758.ref027]\]. In this study, we discovered that an active component of deer's antlers can exerts its pharmacological effects on the inhibition of eosinophil chemotaxis. PLAG inhibits the phosphorylation and activation of STAT6 transcription factor, which results in the down-regulation of an eosinophil chemotactic molecule, CCL26.

Eosinophil infiltration into the allergic inflammatory tissues is mediated by a combination of various processes. Chemokine ligands for CCR3 are important eosinophil chemotactic factors because this receptor is strongly expressed by eosinophils. Reported ligands for this receptor include RANTES (CCL5), MCP-3 (CCL7), MCP-2 (CCL8), eotaxin-1 (CCL11), MCP-4 (CCL13), TARC (CCL17), eotaxin-2 (CCL24), and eotaxin-3 (CCL26). Our RT-PCR data showed that CCL26 is effectively inhibited by PLAG treatment ([Fig 1A](#pone.0151758.g001){ref-type="fig"}). The expression of CCL7 was also inhibited by PLAG although the inductive effect of IL-4 was not detected. CCL7 has been identified as a monocyte attractant produced from certain tumor cells and macrophage \[[@pone.0151758.ref028]\], and shown to function as a chemotactic for eosinophil infiltration into the lung tissues in T~H~2-type pulmonary granuloma, which was blocked by anti-IL-4 treatment \[[@pone.0151758.ref029]\]. In A549 lung epithelial cells, IL-4 and PLAG treatment synergistically blocked CCL7 expression ([Fig 1A](#pone.0151758.g001){ref-type="fig"}). The experimental analysis of PLAG effect on CCL7 expression and eosinophil transmigration in asthma model would be informative for identifying the functional mechanism of PLAG completely.

The expression of Eotaxin family is regulated by two separate pathways, which induce the activation of STAT6 or NF-κB respectively \[[@pone.0151758.ref030], [@pone.0151758.ref031]\]. IL-4/IL-13 simulated pathway causes the activation of STAT6 to induce eotaxin, mainly CCL26 (Eotaxin-3) expression, while TNF-α/IFN-γ mediated pathway activate NF-κB of which the main target is CCL11 (Eotaxin-1). According to an OVA-induced asthma model experiment using STAT6-/- mice, airway eosinophilia was blocked by reducing eotaxin level in the pulmonary tissues \[[@pone.0151758.ref032]\]. The pulmonary eosinophilia in STAT6-/- mice was reconstituted by the intranasal administration of recombinant eotaxin. In addition, STAT6-/- eosinophils have reduced migratory activities and are unable to induce the development of allergic airway inflammation \[[@pone.0151758.ref033]\]. These data suggest STAT6 is a master regulator of eosinophil transepithelial migration by regulating both the production of Eotaxin from epithelial cells and the responsiveness of eosinophils to Eotaxin. STAT6 regulatory activity of PLAG can be used to modulate eosinophil chemotaxis in inflammatory environments. We have demonstrated that PLAG inhibits the invasion of eosinophils in vitro ([Fig 5](#pone.0151758.g005){ref-type="fig"}), and the infiltration of eosinophils in in vivo model (Figs [3](#pone.0151758.g003){ref-type="fig"} and [4](#pone.0151758.g004){ref-type="fig"}). The study of intracellular signaling mechanism has demonstrated PLAG regulates the transcriptional activity of STAT6 to modulated CCL26 expression ([Fig 2](#pone.0151758.g002){ref-type="fig"}). Additionally, PLAG has been reported to modulate T~H~2 immunity by regulating the expression of IL-4 which is also controlled by STAT6 \[[@pone.0151758.ref022]\]. We could conclude that PLAG is effective in immune-modulation by regulating STAT6 activity, which result in the control of T~H~2 immunity and eosinophil transmigration.

The distinctive up-regulation of CCL26 makes this chemokine an important mediator for eosinophil recruitment in chronic allergic asthma. In mice, CCL26 has been identified as a pseudogene, which exhibits a significant sequence homology with human CCL26 \[[@pone.0151758.ref034]\]. To verify the expression of CCL26 in mice, we have thoroughly analyzed RNA transcript by RT-PCR using several primer pairs, and discovered murine CCL26 expression was induced by inflammation ([S1 Fig](#pone.0151758.s001){ref-type="supplementary-material"}). Recent study using a mouse model has showed that intraperitoneal injection of recombinant human CCL26 induced rapid recruitment of mouse eosinophils \[[@pone.0151758.ref035]\]. In addition, the increase of CCL26 protein in the BALF of OVA-induced asthmatic mice has been reported recently \[[@pone.0151758.ref027]\]. Our eosinophil migration assay data verified that human CCL26 is active on the induction of mouse eosinophil migration demonstrating there are cross reactivity between human CCL26 and its mouse counterpart, CCR3, which is a receptor for Eotaxin family proteins in granulocytes ([Fig 5](#pone.0151758.g005){ref-type="fig"}).

Many studies have shown that the production of CCL26 involves JAK1/STAT6 signaling pathway \[[@pone.0151758.ref023], [@pone.0151758.ref036], [@pone.0151758.ref037]\]. We observed that PLAG diminishes STAT6 phosphorylation in the cytoplasm and its transcriptional activity in the nucleus. It is less possible that PLAG bind directly with STAT6 molecules to interfere its phosphorylation because PLAG is a lipid molecule. Instead, it may regulate upstream signaling molecules such as JAK1 and protein kinase C (PKC) \[[@pone.0151758.ref038]\]. In conclusion, PLAG inhibited the production of CCL26 from the epithelial cells by regulating IL-4/JAK1/STAT6 signaling pathway modulating the transmigration of eosinophils. Therefore, we expect that PLAG could be developed as a therapeutic agent for asthma treatment.

Supporting Information {#sec023}
======================

###### The expression of CCL26 was detected in the lung tissues from LPS-challenged mice.

**A**. Coding sequence for mouse CCL26 was depicted, and primer sequences were marked with bottom line. Mouse CCL26 has been predicted to contain three exons, which was displayed in color codes; blue for exon1, orange for exon2, and green for exon3. **B**. The expression of mouse CCL26 was induced by LPS challenge. **C**. DNA sequence of PCR product in B was compared with the predicted sequence (NM_001013412), which showed 100% homology.

(PSD)

###### 

Click here for additional data file.
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PLAG

:   1-palmitic acid-2-linoleic acid-3-acetyl-rac-glycerol

CCL26

:   chemokine (C-C motif) ligand 26

CCR3

:   C-C chemokine receptor 3

IL-4

:   interleukin 4

STAT6

:   signal transducer and activator of transcription 6
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